Search Results

There are 9417 results for: content related to: Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors

  1. You have free access to this content
    Learning From Estrogen Receptor Antagonism: Structure-Based Identification of Novel Antiandrogens Effective Against Multiple Clinically Relevant Androgen Receptor Mutants

    Chemical Biology & Drug Design

    Volume 79, Issue 3, March 2012, Pages: 300–312, Bing Liu, Guoyan Geng, Rongtuan Lin, Cuiyan Ren and Jian Hui Wu

    Article first published online : 11 JAN 2012, DOI: 10.1111/j.1747-0285.2011.01290.x

  2. You have free access to this content
    Suppression of mutant androgen receptors by flutamide

    International Journal of Urology

    Volume 16, Issue 5, May 2009, Pages: 516–521, Junichiro Ishioka, Shuntaro Hara, John T Isaacs, Arihiro Tomura, Kiyohiro Nishikawa and Yukio Kageyama

    Article first published online : 6 APR 2009, DOI: 10.1111/j.1442-2042.2009.02284.x

  3. Non-steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer

    Intervention Review

    The Cochrane Library

    Frank Kunath, Henrik R Grobe, Gerta Rücker, Edith Motschall, Gerd Antes, Philipp Dahm, Bernd Wullich and Joerg J Meerpohl

    Published Online : 30 JUN 2014, DOI: 10.1002/14651858.CD009266.pub2

  4. Bicalutamide (Casodex®) in the treatment of prostate cancer: History of clinical development

    The Prostate

    Volume 34, Issue 1, 1 January 1998, Pages: 61–72, Geert J.C.M. Kolvenbag, George R.P. Blackledge and Karen Gotting-Smith

    Article first published online : 7 DEC 1998, DOI: 10.1002/(SICI)1097-0045(19980101)34:1<61::AID-PROS8>3.0.CO;2-N

  5. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors

    The Prostate

    Volume 72, Issue 8, 1 June 2012, Pages: 875–885, Christian Thomas, Latif A. Wafa, Francois Lamoureux, Helen Cheng, Ladan Fazli, Martin E. Gleave and Paul S. Rennie

    Article first published online : 5 OCT 2011, DOI: 10.1002/pros.21490

  6. You have free access to this content
    Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: Informed scheduling of the bioreductive drug AQ4N improves treatment response

    International Journal of Cancer

    Volume 132, Issue 6, 15 March 2013, Pages: 1323–1332, Louise Ming, Niall M. Byrne, Sarah Nicole Camac, Christopher A. Mitchell, Claire Ward, David J. Waugh, Stephanie R. McKeown and Jenny Worthington

    Article first published online : 23 NOV 2012, DOI: 10.1002/ijc.27796

  7. You have free access to this content
    Enantiomer Selective Glucuronidation of the Non-Steroidal Pure Anti-Androgen Bicalutamide by Human Liver and Kidney: Role of the Human UDP-Glucuronosyltransferase (UGT)1A9 Enzyme

    Basic & Clinical Pharmacology & Toxicology

    Volume 113, Issue 2, August 2013, Pages: 92–102, Laurent Grosse, Anne-Sophie Campeau, Sarah Caron, Frédéric-Alexandre Morin, Kim Meunier, Jocelyn Trottier, Patrick Caron, Mélanie Verreault and Olivier Barbier

    Article first published online : 20 MAY 2013, DOI: 10.1111/bcpt.12071

  8. Bicalutamide dosages used in the treatment of prostate cancer

    The Prostate

    Volume 39, Issue 1, 1 April 1999, Pages: 47–53, Geert J.C.M. Kolvenbag and Anthony Nash

    Article first published online : 3 MAR 1999, DOI: 10.1002/(SICI)1097-0045(19990401)39:1<47::AID-PROS8>3.0.CO;2-X

  9. You have free access to this content
    Androgens regulate Hedgehog signalling and proliferation in androgen-dependent prostate cells

    International Journal of Cancer

    Volume 131, Issue 6, 15 September 2012, Pages: 1297–1306, Nanor Sirab, Stéphane Terry, Frank Giton, Josselin Caradec, Mihelaiti Chimingqi, Stéphane Moutereau, Francis Vacherot, Alexandre de la Taille, Jean-Claude Kouyoumdjian and Sylvain Loric

    Article first published online : 27 JAN 2012, DOI: 10.1002/ijc.27384

  10. Anti-Tumor Effects and Pharmacokinetics of S-40542, a Novel Non-Steroidal Anti-Androgen, in Mice

    LUTS: Lower Urinary Tract Symptoms

    Volume 5, Issue 1, January 2013, Pages: 44–51, Hiroaki NEJISHIMA, Noriko YAMAMOTO, Mika SUZUKI, Kazuyuki FURUYA, Mitsuo MIMURA and Shizuo YAMADA

    Article first published online : 25 MAY 2012, DOI: 10.1111/j.1757-5672.2012.00159.x

  11. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

    BJU International

    Volume 105, Issue 8, April 2010, Pages: 1074–1081, Peter Iversen, David G. McLeod, William A. See, Thomas Morris, Jon Armstrong, Manfred P. Wirth and on behalf of the Casodex Early Prostate Cancer Trialists’ Group

    Article first published online : 25 MAR 2010, DOI: 10.1111/j.1464-410X.2010.09319.x

  12. The intracellular and nuclear-targeted delivery of an antiandrogen drug by carrier peptides

    Peptide Science

    Volume 90, Issue 5, 2008, Pages: 595–603, Jason Hodoniczky, Colette G. Sims, Wayne M. Best, Jacqueline M. Bentel and Jacqueline A. Wilce

    Article first published online : 19 MAR 2008, DOI: 10.1002/bip.20986

  13. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer

    BJU International

    Volume 110, Issue 11, December 2012, Pages: 1729–1735, Mari Nakabayashi, Lilian Werner, Kevin D. Courtney, Geoffrey Buckle, William K. Oh, Glen J. Bubley, Julia H. Hayes, Douglas Weckstein, Aymen Elfiky, Danny M. Sims, Philip W. Kantoff and Mary-Ellen Taplin

    Article first published online : 29 AUG 2012, DOI: 10.1111/j.1464-410X.2012.11456.x

  14. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration

    BJU International

    Volume 98, Issue 3, September 2006, Pages: 563–572, CHRIS J. TYRRElL, PETER IVERSEN, TEUVO TAMMELA, JOHN ANDERSON, THOMAS BJÖRK, AMIR V. KAISARY and THOMAS MORRIS

    Article first published online : 8 JUN 2006, DOI: 10.1111/j.1464-410X.2006.06275.x

  15. Bicalutamide-Associated Fulminant Hepatotoxicity

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 28, Issue 8, August 2008, Pages: 1071–1075, Dr. Cindy L. O'Bryant, Dr. Thomas W. Flaig and Dr. Kenneth J. Utz

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.28.8.1071

  16. Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer

    BJU International

    Volume 107, Issue 12, June 2011, Pages: 1923–1929, Vivek K. Wadhwa, Robin Weston and Nigel J. Parr

    Article first published online : 15 OCT 2010, DOI: 10.1111/j.1464-410X.2010.09726.x

  17. THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF THE BICALUTAMIDE (‘CASODEX’) ENANTIOMERS

    Biopharmaceutics & Drug Disposition

    Volume 18, Issue 6, August 1997, Pages: 499–507, I. D. COCKSHOTT, S. D. OLIVER, J. J. YOUNG, K. J. COOPER and D. C. JONES

    Article first published online : 4 DEC 1998, DOI: 10.1002/(SICI)1099-081X(199708)18:6<499::AID-BDD37>3.0.CO;2-J

  18. You have free access to this content
    Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro

    International Journal of Cancer

    Volume 115, Issue 4, 1 July 2005, Pages: 630–640, Claudio Festuccia, Giovanni Luca Gravina, Adriano Angelucci, Danilo Millimaggi, Paola Muzi, Carlo Vicentini and Mauro Bologna

    Article first published online : 7 FEB 2005, DOI: 10.1002/ijc.20917

  19. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer

    The Prostate

    Volume 73, Issue 12, September 2013, Pages: 1291–1305, Javier Guerrero, Iván E. Alfaro, Francisco Gómez, Andrew A. Protter and Sebastián Bernales

    Article first published online : 13 JUN 2013, DOI: 10.1002/pros.22674

  20. The role of antiandrogen monotherapy in the treatment of prostate cancer

    BJU International

    Volume 91, Issue 5, March 2003, Pages: 455–461, J. Anderson

    Article first published online : 26 FEB 2003, DOI: 10.1046/j.1464-410X.2003.04026.x